SPHS Stock - Sophiris Bio, Inc.
Unlock GoAI Insights for SPHS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,094,000 | $-8,421,000 | $-10,872,000 | $-13,507,000 | $-29,986,000 |
| Net Income | $-7,462,000 | $-8,835,000 | $-11,456,000 | $-14,887,000 | $-31,438,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.25 | $-0.29 | $-0.50 | $-0.88 | $-1.90 |
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Visit WebsiteEarnings History & Surprises
SPHSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2019 | Sep 30, 2019 | — | $-0.03 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.08 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.08 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.46 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.10 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.24 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.12 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.15 | — | — |
Q3 2017 | Sep 30, 2017 | — | $-0.09 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.02 | — | — |
Q1 2017 | Mar 31, 2017 | — | $-0.09 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.03 | — | — |
Q3 2016 | Sep 30, 2016 | — | $-0.17 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.22 | — | — |
Q1 2016 | Mar 31, 2016 | — | $-0.14 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.16 | — | — |
Q3 2015 | Sep 30, 2015 | — | $-0.23 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.23 | — | — |
Q1 2015 | Mar 31, 2015 | — | $-0.27 | — | — |
Q4 2014 | Dec 31, 2014 | — | $-0.32 | — | — |
Latest News
Frequently Asked Questions about SPHS
What is SPHS's current stock price?
What is the analyst price target for SPHS?
What sector is Sophiris Bio, Inc. in?
What is SPHS's market cap?
Does SPHS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SPHS for comparison